BioFocus is collaborating with the Michael J. Fox Foundation for Parkinson’s Research, on the discovery and development of diagnostics for Parkinson disease. The agreement will see BioFocus carry out fragment-based screening, assay development, and hit-finding programs.
As the service division of Galapagos, BioFocus offers target to candidate drug discovery services to the industry worldwide. Headquartered in the U.K., the firm has facilities in the U.S. and Switzerland, and sales offices in Japan, Singapore, and the U.S.
BioFocus’s suite of discovery products and services are available either separately or as an integrated drug discovery solution backed by a central project management system. Services include target discovery, assay development/screening, structural biology, in silico drug discovery, medicinal chemistry, ADME/PK, and compound libraries.
The latest collaboration with the Michael J. Fox Foundation comes less than a month after BioFocus announced expanding its existing drug discovery collaboration with the Usher III Initiative, a nonprofit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. Under the terms of the extended agreement, BioFocus aims to develop and deliver a preclinical candidate.
Earlier in June BioFocus reported the agreed sale of its U.S.-based compound-management business, Compound Focus, to Evotec, for €10.25 million in cash up front, and potentially an additional €2.25 million in performance-based payments.